Table 2.

Patient demographics and baseline characteristics

CharacteristicsValue (range)
Patients, n 34
Median age, y (range)62 (46–79)
Body weight, kg (range)78 (54–128)
Sex, n (%)
 Male24 (71%)
 Female10 (29%)
Race, n (%)
 White30 (88%)
 Black or African heritage2 (6%)
 Asian1 (3%)
 Other1 (3%)
Performance status; ECOG, n (%)
 019 (56%)
 114 (41%)
 21 (3%)
Median time since diagnosis, y (range)5.7 (1.6–19)
M-component, n (%)
 IgG25 (74%)
 IgA6 (18%)
 IgD1 (3%)
 Free light chain disease (kappa)2 (6%)
Prior multiple myeloma treatments
 Median no., n (range)6 (2–12)
 Autologous stem cell transplant, n (%)29 (85%)
 Any IMiDs in earlier treatments, n (%)27 (79%)
  Lenalidomide, n (%)21 (62%)
  Thalidomide, n (%)23 (68%)
 Bortezomib in earlier treatments, n (%)29 (85%)